Hypothesis 1: 18F-Fluciclovine PET/CT can correctly and easily identify the pancreatic allograft and determine its viability Aim 1: Assess whether 18F-Fluciclovine can identify the pancreatic allograft accurately and assess its viability and visibility Hypothesis 2: 18F-Fluciclovine PET/CT uptake in the pancreas (SUV) is related to total pancreatic function and therefore can indicate whether the pancreatic allograft is at risk of rejection Aim 2: Assess whether 18F-Fluciclovine uptake in the pancreas can be a surrogate for pancreatic function
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Measurement of Pancreatic Allograft Viability after 18F-Fluciclovine Utilization
Timeframe: This outcome will be measured after the radiologic images have been processed and archived (within 24 hours of intervention) and laboratory results are certified (within 24 hours of intervention).
Measurement of Pancreatic Allograft Visibility after 18F-Fluciclovine Utilization
Timeframe: These reviews will take place within 72 hours of the radiologic imaging taking place for each participant.
Measurement of Pancreatic Allograft Uptake after 18F-Fluciclovine Utilization
Timeframe: This outcome will be measured after the radiologic images have been processed and archived (within 72 hours of intervention).